The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2009
DOI: 10.14573/altex.2009.3.187
|View full text |Cite
|
Sign up to set email alerts
|

Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the Transatlantic Think Tank for Toxicology (t4)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
191
0
1

Year Published

2010
2010
2018
2018

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 221 publications
(194 citation statements)
references
References 16 publications
(22 reference statements)
2
191
0
1
Order By: Relevance
“…OECD 421, or 422) produced at more than 10 tons. The costs of this in vitro testing is around 10 times lower than the in vivo testing, which in its cheapest version costs around 55,000 Euro [48]. Expert judgment still is needed in different situations to interpret the outcomes, e.g.…”
Section: Module 4 Data Integration and Risk Assessmentmentioning
confidence: 99%
“…OECD 421, or 422) produced at more than 10 tons. The costs of this in vitro testing is around 10 times lower than the in vivo testing, which in its cheapest version costs around 55,000 Euro [48]. Expert judgment still is needed in different situations to interpret the outcomes, e.g.…”
Section: Module 4 Data Integration and Risk Assessmentmentioning
confidence: 99%
“…Thus, the gold standard used for the identification of contact sensitizers, the local lymph node assay (LLNA) [2,3], can no longer be used. The EU Chemicals Directive REACh would require a vast numbers of animals for retesting of more than 30,000 chemicals to assess their sensitizing potential [4][5][6][7]. International programmes have been established for the development of in vitro alternatives to animal testing in different areas of toxicology.…”
Section: Replacement Of Animal Testing: T Cells As Tools In Immunotoxmentioning
confidence: 99%
“…First, skin sensitisation is an economically relevant endpoint because the number of people suffering from ACD has been increasing world-wide for many years (Thyssen et al,Introduction 6 chemicals under REACH suggest 162.8 billion Euros for the total number of chemicals, considering a moderate scenario on the animal tests requirements (Rovida and Hartung, 2009). Under the same moderate scenario, animal tests for skin sensitisation, such as the Local Lymph Node Assay (LLNA) (Kimber et al, 1994;Kimber et al, 2001) described in the OECD TG 429 (OECD, 2010) and guinea pig based tests described in the OECD TG 406 (OECD, 1992), are estimated to require the use of about 823,891 animals in order to meet the requirements of REACH (Rovida and Hartung, 2009).…”
Section: Addressing the Development Of Efficient Toxicity Testing Strmentioning
confidence: 99%
“…Under the same moderate scenario, animal tests for skin sensitisation, such as the Local Lymph Node Assay (LLNA) (Kimber et al, 1994;Kimber et al, 2001) described in the OECD TG 429 (OECD, 2010) and guinea pig based tests described in the OECD TG 406 (OECD, 1992), are estimated to require the use of about 823,891 animals in order to meet the requirements of REACH (Rovida and Hartung, 2009). To achieve cost minimisation in the development of testing strategies, it is important to further study the integration of information about direct testing costs, animal welfare considerations and indirect costs from the increasing occurrence of ACD, the clinically relevant effect of skin sensitisation, in the development of testing strategies for assessing skin sensitisation.…”
Section: Addressing the Development Of Efficient Toxicity Testing Strmentioning
confidence: 99%
See 1 more Smart Citation